Scope
This 42-page report gives important, expert insight that you won’t find in any other source. 13 curated figures throughout the report illustrate major points and trends relating to RNA-Based drugs and the impact of COVID-19. This report is required reading for:- Investors that want to understand the current and future RNA-Based drug trends, as well as identifying companies to invest in.
- Companies that are interesting in identifying the current landscape for RNA-Based drugs, as well as the forecast future landscape.
- Large companies with investment groups or BD teams looking to see which companies are predicted to lead the RNA-Based drug landscape in the near and far future.
- Small and medium pharma who want to focus their drug portfolio on future trends regarding RNA technology, and are looking for partnership opportunities.
Reasons to Buy
- Insights on RNA-Based Drug Approval trends
- Insights on active companies with RNA-Based drugs
- Insights on RNA-Based drugs by development stage
- Insights on deals involving RNA-Based drugs
- Insights on RNA-Based drug clinical trial trends
- Insights on RNA-Based forecast sale values
- Insights on major upcoming RNA-Based Drug launches
Table of Contents
1 Executive Summary
2 RNA-Based Drugs and the Impact of COVID-19
2.1 An introduction to RNA-based drugs
2.2 The impact of COVID-19
3 An Overview of the Current RNA-Based Drug Landscape
3.1 Approval timeline of RNA-based drugs
3.2 Top companies in RNA technology
3.3 RNA drugs by development stage
3.4 Yearly change in active RNA-based drug count
4 Major Post-Pandemic Changes to the RNA-Based Landscape
4.1 Changes in deal volume and deal values
4.2 Awarding of review designation by molecule type
4.3 Changes of clinical trial trends
5 RNA-Based Drugs; The Future Perspective
5.1 RNA drug sales by therapy area, company and molecule type
5.2 Top upcoming RNA-based drug launches
6 Key Findings
7 Appendix
7.1 Abbreviations
7.2 Methodology
7.3 Related Reports
7.4 About the Authors
7.5 About the Publisher
7.6 Contact the Publisher
